Overview
Pseudobulbar palsy (PBA) involves involuntary episodes of laughing and/or crying that are disproportionate to the emotional state, often observed in patients with neurological disorders 1.Diagnosis
Characterized by unprovoked and uncontrollable emotional outbursts 1.
Diagnosis typically clinical, based on symptom presentation and exclusion of other causes 1.
No specific laboratory tests; imaging or neurological exams may help rule out underlying conditions 1.Management
First-line treatment: Dextromethorphan-quinidine (DMQ) combination, FDA approved for PBA 1.
Adjunctive measures: Non-pharmacological interventions such as psychotherapy and support groups may complement pharmacological treatment 1.
Alternative formulations: Compounded DMQ suspension can be considered for patients unable to swallow solid or semisolid medications 1.Special Populations
Elderly: Hospice patients may benefit from compounded DMQ suspension for symptom management when conventional formulations are not feasible 1.Key Recommendations
Consider compounded dextromethorphan-quinidine suspension for managing PBA in hospice patients who cannot tolerate solid or semisolid medications (Evidence: Weak 1).
Prioritize FDA-approved dextromethorphan-quinidine for first-line pharmacological treatment of PBA (Evidence: Expert opinion 1).
Evaluate and consider non-pharmacological support alongside pharmacological interventions for comprehensive management (Evidence: Expert opinion 1).References
1 Wahler RG, Reiman AT, Schrader JV. Use of Compounded Dextromethorphan-Quinidine Suspension for Pseudobulbar Affect in Hospice Patients. Journal of palliative medicine 2017. link